Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Colitis, Ulcerative Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

11 recruiting trials for Colitis, Ulcerative. Eligibility criteria explained in plain English.

TrialFinderData lists 11 Colitis, Ulcerative clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 3 is the largest group at 67% (2 studies); the largest phase groups are Phase 3: 2, Phase 2: 1.

Research is led by University of Thessaly (1), Eisai Korea Inc. (1), Xijing Hospital (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Dietary supplement intervention Goodphyte IB Defense (dietary_supplement, 1 trial), followed by Dietary supplement intervention Goodphyte Immunity, Non-interventional.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
11
Total Trials
11
Recruiting Now
2
Phase 3 Trials
10
Sponsors

Track Colitis, Ulcerative trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT07380022

Acceptability, Adherence, and Impact on the Bioavailability of Iron and Zinc of the Dietary Supplements Goodphyte IB...

The primary objective of the present postdoctoral research is to evaluate the acceptability and adherence of two dietary supplements containing microbial phytase, Goodphyte IB...

Sponsor: University of ThessalyEnrolling: 1001 location
RECRUITINGNCT06246123

A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants

The purpose of this study is to collect and evaluate the following information in relation to the safety and the efficacy of Jyseleca tablet (Filgotinib Maleate) 100 milligram...

Sponsor: Eisai Korea Inc.Enrolling: 204020 locations
RECRUITINGNCT06995170

Investigation of the Correlation Between Polyamine Levels and Their Key Enzymatic Activities in Association With...

Inflammatory Bowel Disease (IBD), encompassing Ulcerative Colitis (UC) and Crohn's Disease (CD), significantly impairs patients' quality of life. Current monitoring of disease...

Sponsor: Xijing HospitalEnrolling: 1461 location
RECRUITINGNCT07532213

A Study to Assess Real-world Outcomes for Long-Term Use of Guselkumab

The purpose of this study is to evaluate how long guselkumab remains in participants with moderate to severe crohn's disease (CD) or ulcerative colitis (UC) in real-world setting....

Sponsor: Janssen-Cilag A.G., SwitzerlandEnrolling: 501 location
RECRUITINGNCT07242248

A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's...

The purpose of this study is to evaluate the clinical effectiveness (how well the treatment works) of Guselkumab, by lines of treatment and subpopulations, and what are the...

Sponsor: Janssen-Cilag Ltd.Enrolling: 2201 location
RECRUITINGPhase 3NCT06660693

Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis

This study aims to examine patients with acute severe UC who are refractory to intravenous corticosteroids and determine whether a strategy of using upadacitinib first followed by...

Sponsor: McMaster UniversityEnrolling: 1341 location
RECRUITINGPhase 3NCT07577856

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to...

Sponsor: Janssen Research & Development, LLCEnrolling: 6446 locations
RECRUITINGPhase 2NCT07012395

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC). The primary goal of the study is...

Sponsor: Spyre Therapeutics, Inc.Enrolling: 64520 locations
RECRUITINGNCT05456412

JAK Inhibition in Ulcerative Colitis

The treatment for Ulcerative Colitis (UC) aims to achieve and maintain remission and is usually lifelong and expensive. Current available medications are unable to break the cycle...

Sponsor: Leiden University Medical CenterEnrolling: 601 location
RECRUITINGNCT06294925

A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis

The purpose of this real world non-interventional study is to learn about the effects of etrasimod as treatment for patients with moderate to severe ulcerative colitis. Patients...

Sponsor: PfizerEnrolling: 36020 locations
RECRUITINGNCT04121806

Diet Intervention Treatment for Active Ulcerative Colitis

The purpose of this study is to determine if a sustainable non-elemental diet can be used as a probiotic tool to alter the dysbiotic microbiome found in individuals with...

Sponsor: Mount Sinai Hospital, CanadaEnrolling: 201 location

Frequently Asked Questions

There are currently 11 clinical trials for Colitis, Ulcerative, with 11 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Colitis, Ulcerative, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 2 Phase 3 trials for Colitis, Ulcerative, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.